Detalles de la búsqueda
1.
Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study.
Am J Hematol
; 89(2): 174-80, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24123244
2.
Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC).
Bone Marrow Transplant
; 2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38664589
3.
Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation.
Blood
; 117(5): 1516-21, 2011 Feb 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-21106985
4.
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).
J Clin Oncol
; 35(19): 2157-2164, 2017 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28463633
5.
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
J Clin Oncol
; 30(20): 2475-82, 2012 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-22585692
Resultados
1 -
5
de 5
1
Próxima >
>>